Last close As at 05/08/2026
GBP1.04
▲ 6.95 (7.15%)
Market capitalisation
GBP2,539m
Research: Metals & Mining
Pan African’s EPS for H126 were 2.7% ahead of our prior forecasts on a headline basis and 27.0% ahead on a normalised basis (see Exhibit 2). Management reiterated guidance for FY26 at 275–292koz, albeit at a slightly higher AISC of
| Year end | Revenue ($m) | PBT ($m) | EPS (¢) | DPS (¢) | P/E (x) | Yield (%) |
|---|---|---|---|---|---|---|
| 6/24 | 373.8 | 119.8 | 4.68 | 1.24 | 51.0 | 0.5 |
| 6/25 | 540.0 | 201.5 | 7.40 | 2.10 | 32.3 | 0.9 |
| 6/26e | 1,255.0 | 732.6 | 24.77 | 8.10 | 9.6 | 3.4 |
| 6/27e | 1,054.4 | 530.2 | 19.07 | 6.27 | 12.5 | 2.6 |
After more than 15 years, this will be Edison’s last note on Pan African for the foreseeable future. In our first note, PAF had a share price of 10.25p and a market capitalisation of £148m. We think this performance speaks for itself and we wish management and the company all the very best for the future.
Based on its six principal producing assets, our core valuation of Pan African has
moderated by 7.1% to 51.70c per share (cf 55.65c previously), based largely on lower
production and higher capital expenditure guidance for FY27 (although note that the
higher longer-term production from Tennant in particular that might be expected to
attend higher FY27 capital expenditure may not be fully captured in our financial
model) and the relentless rise of the rand. It rises by a further 37.99–43.01c to
89.69–94.71c (66.67–70.41p) if other assets, such as Egoli and the Soweto Cluster,
are also taken into account. However, all these valuations are calculated at Edison’s
long-term (real) gold price of
Pan African’s production in H126 was exactly in line with both our expectations and
prior guidance (provided in its Operational update of 26 January) with the single exception of the fact that 3,227oz of Evander’s output was derived
from surface sources, rather than underground (Exhibit 1). Financially, five out of
seven operations (ie all except Barberton and Evander surface) recorded record adjusted
EBITDA (see Exhibit 3), which contributed towards record group profitability (Exhibit
5) and a maiden ZAR0.12/share interim dividend. Guidance for FY26 was reiterated at
275–292koz, albeit at a higher all-in sustaining cost (AISC) of
Relative to our prior forecasts (Exhibit 2), the most obvious variances were:
Exhibit 2, below, summarises PAF’s H126 results, relative to both our prior expectations and prior year results (as reported, rather than adjusted).
Operationally, production at MTR/Mogale was approximately 10% lower than expected by management, as a result of mined grades and recoveries that were adversely affected by the intersection of an anomalous low-grade lens of low-recovery calcine material that reduced both mining grade and recoveries.
Elsewhere, the ramp-up of tonnes at Evander associated with the start of major mining activities at 25 & 26 Level was delayed, with mill throughput at almost exactly the level of H225, albeit this was achieved at a materially higher grade and a lower unit cost (see Exhibit 4).
Nevertheless, both achieved record adjusted EBITDA, along with the BTRP, Elikhulu and Tennant/Nobles, in both US dollar and rand terms:
Notably good unit production costs in local currency per tonne processed terms were recorded at Barberton, BTRP and Tennant/Nobles (relative to our prior forecasts), despite above inflation increases in the prices of reagents, annual salary increases and a 12.7% regulatory increase in the electricity tariff (albeit mitigated by PAF’s solar initiatives). Production at Tennant/Nobles in H226 is also anticipated to increase to c 30,000oz as higher-grade ore from open pits replaces lower-grade feed from the Crown Pillar Stockpile.
As a result, we have adjusted our H226 operational performance expectations to those
shown in Exhibit 4, below. In general, our production expectations have remained almost
unchanged. However, we have revised our cost assumptions as well as our estimate of
the gold price for the remainder of the financial year to June to
Taking all of these factors into account, we have revised our HEPS forecasts for the group for FY26 up by 3.8% and our normalised HEPS forecast by 11.6%, as shown in Exhibit 5, below.
A comparison between Edison and consensus forecasts for FY26 is provided in Exhibit 6:
In addition to its H126 results, Pan African also provided production guidance for FY27. Readers are directed to Pan African’s results announcement for the details of this guidance. In summary however:
Overall therefore, guidance for production in FY27 is 270–302koz, broken down as follows:
Edison’s detailed forecast for FY27 is 291.6koz, which is 10.6% below our previous (pre-guidance) forecast of 326.1koz. However, we would then expect output to expand to 347.3koz (±5.1%) with increases at Barberton (to its steady-state level), Evander (as the 24 & 25 Level project hits its stride), MTR (as mine sequencing develops in its favour) and Tennant/Nobles (in line with management’s updated production profile):
A feasibility study to process PAF’s Soweto Cluster TSF as a standalone operation was successfully completed in H126, the results of which were announced on 27 November 2025 (see our note Bringing Soweto to the fore, published on 17 December 2025). A definitive feasibility study (DFS) for a plant with expected annual gold production of 30–35koz over 15 years is expected to be completed by June. Additional expansion projects to those already considered include:
In addition to production guidance, PAF also provided updated capital expenditure
guidance for FY26 and FY27. While guidance for FY26 was 20.9% (or
As noted previously, however, this valuation is conducted at Edison’s relatively conservative
long-term gold price assumption of a
Even so, including its other growth projects and assets, our updated total valuation of PAF as a whole rises to 89.69–94.71c per share (66.67–70.41p).
Exhibit 13 below depicts PAF’s average share price in each of the financial years from FY10 to FY25 and compares this with HEPS in the same year. For FY26 and FY27, the predicted share price is shown, given our forecast normalised HEPS for those years (as per the paragraph below Exhibit 13). As is apparent from the chart, PAF’s price to normalised HEPS ratios of 9.7x for FY26, in particular, remains towards the middle of its recent historical range of 4.1–14.8x for the period FY10–25:
If PAF’s average year one price to normalised EPS ratio of 8.1x for the period FY10–25 is applied to our updated normalised earnings forecasts, it implies a share price for PAF of 148.9p in FY26 followed by one of 114.5p in FY27 (as shown Exhibit 13). Stated alternatively, PAF’s current share price of 179p, at prevailing foreign exchange rates, appears to be discounting FY26 and/or FY27 normalised HEPS of 29.80c per share (cf our forecasts of 24.77c and 19.07c, respectively). However, readers should note that, should the current price of gold prevail until June 2027, our FY27 normalised HEPS forecast increases to 34.18c, in which case our corresponding share price increases to 205.3p.
In the meantime, it may be seen that PAF remains cheap relative to its listed international gold mining peers on 52% of comparable common valuation measures (43 out of 82 individual measures in the table below) if Edison forecasts are used or 46% (38 out of 82 measures) if consensus forecasts are used. However, it is cheap on at least 70% of measures (58 out of 82 measures) if the spot price of gold prevails until June 2027.
Applying PAF’s peers’ average year one P/E ratio of 12.9x to our normalised HEPS forecast of 24.77c per share for FY26 implies a share price for the company of 237p at prevailing foreign exchange rates. Applying its peers’ average year two P/E ratio of 9.1x to our normalised HEPS forecast of 19.07c per share for FY27 implies a share price of 129p (at Edison’s gold price) or 231p (at the spot price of gold).
Pan African is a multi-asset company that has shown a willingness and ability to grow production both organically and by acquiring assets in order to maximise shareholder returns. As a result, rather than our customary method of discounting maximum potential dividends over the life of operations back to FY25, in the case of Pan African, we can alternatively discount forecast cash flows back over five years to the start of FY25 and then apply an ex-growth terminal multiple to forecast cash flows in that year (FY30) based on the appropriate discount rate.
In this case, our estimate of PAF’s pre-financing terminal cash flow in FY30 is 6.18c/share
(at a real gold price of
At this point (FY31), production is anticipated to be in the order of 345.3koz. If PAF is able to maintain this level of cash flows per share via organic investment, its valuation will flatten out at 68.95p/share in real terms on an ex-growth basis. However, the gold price alone should afford an additional 4.1% growth per year in real terms (the compound average annual real appreciation rate in its price from 1967 to 2025), in which case, PAF’s terminal valuation almost trebles to 186.94p/share and its current valuation almost doubles to 168.53p/share.
PAF reported net debt of
Unsurprisingly, the group remains very comfortably within its senior debt covenants:
General disclaimer and copyright
This report has been commissioned by Pan African Resources and prepared and issued by Edison, in consideration of a fee payable by Pan African Resources. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.
Copyright 2026 Edison Investment Research Limited (Edison).
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment completed in February 2026 (n=246), top-line data (due in mid-2026) represent the most significant upcoming inflection point. The initiation in January 2026 of the Phase II RESPIRE study (n=96) in hospitalised patients with viral respiratory insufficiency illustrates the dual-track development strategy, targeting both chronic and acute inflammatory settings, and broadens the asset’s addressable opportunity. The RESPIRE top-line data in Q326, together with ADVANCE IIb data, should define resomelagon’s commercial positioning and underpin the scope of partnering discussions. Incorporating FY25 results pipeline progress and the recent SEK51.9m equity raise, our valuation increases to SEK2.21bn (SEK39.3/share) from SEK1.97bn (SEK36.9/share).